



**Press release**

May 12, 2018

Gothenburg

## EmbryoScope+ approved for sales in the USA

**Vitrolife AB (publ) has today received market approval for the time-lapse incubator EmbryoScope+ in the USA, the world's third largest market measured in terms of number of IVF treatments.**

EmbryoScope+ is a time-lapse system with an integrated incubator with a capacity for fifteen patients. Vitrolife is the market leader of time-lapse systems for use in assisted reproduction for undisturbed culture and improved selection of embryos. "We are delighted to now being able to offer also EmbryoScope+ to the clinics in the USA", says Thomas Axelsson, CEO of Vitrolife.

May 12, 2018  
Gothenburg  
VITROLIFE AB (publ)  
Thomas Axelsson, CEO

**Contact persons:**

Thomas Axelsson, CEO, tel: +46 31 721 80 01

Mikael Engblom, CFO, tel: +46 31 721 80 14

---

Vitrolife is an international medical device Group. Vitrolife develops, produces and markets products for assisted reproduction.

Vitrolife today has approximately 370 employees and the company's products are sold in approximately 110 markets. The company is headquartered in Gothenburg, Sweden, and there are also offices in Australia, Belgium, China, Denmark, France, Germany, Italy, Japan, United Kingdom and USA. The Vitrolife share is listed on NASDAQ Stockholm.

---

Vitrolife AB (publ), Box 9080, SE-400 92 Gothenburg. Corporate ID number 556354-3452. Tel: +46 31 721 80 00. Fax: +46 31 721 80 99. E-mail: [info@vitrolife.com](mailto:info@vitrolife.com). Website: [www.vitrolife.com](http://www.vitrolife.com)

This information is information that Vitrolife AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through the agency of the contact persons set out above, at 1.00 pm CET on May 12, 2018.